Navigating Pediatric Inflammatory Skin Conditions in Skin of Color
At the most recent Skin of Color Update, we had the honor to learn about pediatric inflammatory skin conditions from the renowned Dr. Candrice Heath, triple board-certified dermatologist and Associate Professor at the Howard University Department of Dermatology and Dr. Brandi Kenner-Bell, Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine.
…
At the most recent Skin of Color Update, we had the honor to learn about pediatric inflammatory skin conditions from the renowned Dr. Candrice Heath, triple board-certified dermatologist and Associate Professor at the Howard University Department of Dermatology and Dr. Brandi Kenner-Bell, Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine.
… Continue reading "Navigating Pediatric Inflammatory Skin Conditions in Skin of Color"
A 45-year-old man presents to the office with weakness and the lesions on his hand pictured. His symptoms have been progressively worsening over the last 5 months. He works as a nurse and has had difficulty walking up the stairs and lifting patients. He has a history of frontal migraines for which he occasionally takes ibuprofen. He takes a cholesterol lowering medication and is otherwise heal … 
June and July mark a major milestone—you’re wrapping up intern year and are finally starting dermatology residency. You’ve survived night shifts, rapid responses, and figuring out how to juggle clinical demands like a pro. Just when you felt like you were getting the hang of things… you’re resetting the clock and diving headfirst into a specialty that sometimes feels like an entirely dif … 
The July 2025 issue of the Journal of Drugs in Dermatology brings together another outstanding selection of articles, offering cutting-edge insights and real-world strategies across a diverse range of dermatology topics. This month’s editor’s highlights spotlight innovative approaches to photoprotection in melasma and photodamage, emerging non-pharmaceutical solutions for fem … 
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory …